CANADA; ISRAEL —Apotex Health Corp. has acquired the remaining 70% stake in the H. pylori therapy Talicia from RedHill Biopharma Ltd., consolidating full ownership of the commercial product. Under the terms of the divestment agreement, Apotex paid an upfront cash consideration of $18 million and agreed to potential milestone payments totaling up to $35 million tied to future global net sales performance. The transaction follows Apotex's prior purchase of Cumberland Pharmaceuticals' U.S. branded business, which previously held the minor 30% interest in the drug enterprise.
RedHill Biopharma Ltd. is a specialty biopharmaceutical entity specializing in the clinical development and commercialization of therapeutic treatments for gastrointestinal diseases, oncology, and infectious conditions. Apotex Health Corp. operates as a global pharmaceutical company focused on generic, biosimilar, and branded prescription products across international healthcare markets.
The strategic transaction transforms RedHill's balance sheet by monetizing its primary commercial asset to secure non-dilutive capital. The capital injection provides immediate liquidity required to fund the expansion of the company's broader specialty pipeline, which includes late-stage programs in gastrointestinal intolerance, acute gastroenteritis, and oncology therapeutics. Divesting the matured asset allows the organization to realign operational expenditures toward higher-margin commercial assets with larger addressable markets.
The consolidation of Talicia under Apotex expands the acquirer's footprint in specialty gastrointestinal treatments across North American and international markets. For pharmaceutical investors and corporate stakeholders, the transaction reflects ongoing portfolio rationalization trends in the specialty pharma sector, where mid-sized developers monetize commercial-stage drugs to fund research and development pipelines while global distributors leverage scale to optimize commercial execution.
